Advertisement
Surgeons completed radical prostatectomy using new-generation robot
Cleveland Clinic is the first hospital in the country to successfully perform surgeries using the Single Port SP Robot, which inserts all surgical instruments through one small abdominal incision, improving surgical outcomes and allowing quicker patient recovery.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
On Sept. 28, Cleveland Clinic surgeons used the SP Robot to perform three surgeries — two surgeries to remove cancerous prostates and one surgery to remove an enlarged prostate blocking the urinary system through the bladder.
Jihad Kaouk, MD, Director of the Center for Robotic and Image Guided Surgery in the Glickman Urologic and Kidney Institute, was the first to perform and publish on robotic single-port surgery in 2008 using standard robotic systems and coining the phrase R-LESS (robotic laparoendoscopic single site surgery).
After completing and publishing the first ever clinical use for the SP robot in Europe, Dr. Kaouk and his team also performed last week’s radical prostatectomies and transvesical simple prostatectomy at Cleveland Clinic. The new purpose-built robotic SP system will allow the single port approach to be more feasible.
“We anticipate that this new generation of robots will allow for new and different routes of surgeries that haven’t previously been possible,” Dr. Kaouk says. “For example, we can now go through a patient’s perineum instead of their belly to perform prostate surgery and avoid touching the bowel, or work through the retroperitoneal space to perform kidney surgery without entering the abdomen, allowing for quicker recovery time.”
Currently, the SP Robot is only FDA-approved for urologic surgeries, with plans to expand to ENT and colorectal surgeries in the near future.
“We are proud to offer this surgical approach and be on the forefront of surgical innovation,” adds Mark A. Taylor, MD, Chairman of Surgical Operations at Cleveland Clinic.
Advertisement
Dr. Kaouk worked with the Intuitive Inc. team of engineers to test and improve the new robotic system. Dr. Kaouk is a paid consultant, speaker or member of the advisory committee for Endocare, Inc. and Intuitive Surgical, Inc.
Advertisement
Advertisement
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings strengthen evidence for risk-reducing procedures
Findings from large database important to inform clinical practice
Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant
Offers a new option for patients 60 and older with relapsed/refractory disease